Science

Studied in the lab. Clinically validated in humans.

 

A fully-loaded product pipeline in various stages of clinical development, Nobel Prize-winning advisors, partnerships with the University of Oxford and Yale University — and much more. At the heart of each one of our initiatives is a commitment to rigorous scientific research.

Product Pipeline

 

Our current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. Beyond Basis, Matter, Format, Signal, Mosaic, Vision, Cofactor, and Index, we are working with our scientific advisors and university partners to identify promising new research and innovative compounds.

These compounds are all tested for safety and efficacy in placebo-controlled human trials before coming to market.

Clinical Trials

Clinical research is incredibly important to us. We study our products in humans so you can be confident that your decisions are based on scientific evidence.

  • TIME-ZZZ

    The Translational Initiative to Map Epigenetics in Sleep (TIME-ZZZ) is a longitudinal, prospective research study that aims to advance our understanding of the interplay between sleep, mental health, and biological aging. All Index users are eligible to enroll. The study can be found on www.clinicaltrials.gov under the identifier NCT06333301.

  • NADAPT

    Initiated at Haukeland University Hospital, this human clinical trial is evaluating the efficacy of NAD replenishment therapy with NR in delaying disability progression and amelioration of symptoms in patients with atypical parkinsonian syndromes. The estimated study completion date is December 2028. ClinicalTrials.gov Identifier: NCT06162013

  • Progressive MS

    Initiated at Haukeland University Hospital, this human clinical trial is evaluating the safety and efficacy of NR on slowing disability progression in patients with progressive multiple sclerosis. The estimated study completion date is December 2027. ClinicalTrials.gov Identifier: NCT05740722

  • Osteoporosis

    Initiated at Odense University Hospital, this human clinical trial is evaluating the effect of NR-E or senolytics on bone resorption and formation markers in osteoporosis. The estimated study completion date is December 2025. ClinicalTrials.gov Identifier: NCT06018467

  • Age-Related Frailty

    Initiated at Mayo Clinic, the human clinical trial will evaluate whether Elysium’s proprietary nicotinamide riboside (NR-E) can augment bone, skeletal muscle, and metabolic functions and structure in aging. The estimated primary study completion date is December 2024. ClinicalTrials.gov Identifier: NCT03818802

  • TIME-A

    The Translational Initiative to Map Epigenetics in Aging (TIME-A) is a longitudinal, prospective research study that aims to advance our understanding of the connections between epigenetics, lifestyle, demographics, and health and aging. All Index users are eligible to enroll. The study can be found on www.clinicaltrials.gov under the identifier NCT05760547.

  • Slow Age

    Initiated at the University of Copenhagen in Denmark, this human clinical trial evaluated the effects of nicotinamide riboside (NR-E), aerobic exercise, or time-restricted feeding on markers of aging. The study is complete and pending publication. ClinicalTrials.gov Identifier: NCT05593939

  • Brain Vascular Health

    Initiated at the University of Oklahoma, this human clinical trial is evaluating the efficacy of NR-E on supporting brain vascular health and memory in aging. The estimated primary study completion date is June 2027. ClinicalTrials.gov Identifier: NCT05483465

  • Non-Alcoholic Fatty Liver (NAFL)

    This six-month human clinical trial showed that Basis, at the recommended dose, reduced several markers of liver inflammation in healthy adults with fatty liver. The results, published in Hepatology, also further confirmed that Basis is safe and well tolerated and supports liver function in healthy individuals. Publication here. ClinicalTrials.gov Identifier: NCT03513523

  • Muscle Injury and Repair

    Initiated in partnership with researchers at Aarhus University in Denmark, this study demonstrated that a combination of nicotinamide riboside and pterostilbene (NRPT) was well tolerated but did not improve recruitment of muscle stem cells after muscle injury in older adults. Muscle soreness, however, tended to be lower in the treatment group. Publication here. ClinicalTrials.gov Identifier: NCT03754842

  • Acute Kidney Injury (AKI) Phase I

    Completed and published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial. Publication here. ClinicalTrials.gov Identifier: NCT03176628

  • Acute Kidney Injury (AKI) Phase II

    Initiated at Mayo Clinic, this human clinical trial is evaluating the efficacy of Basis for the prevention of AKI in surgical cardiac patients. This study is complete and pending publication. ClinicalTrials.gov Identifier: NCT04342975

  • Repeat Dose Basis

    Elysium’s first human clinical trial showed that a daily dose of Basis safely and sustainably increases NAD+ levels by an average of 40% from baseline–by middle age, our NAD+ levels decline by approximately 50%. The study was published in Nature Partner Journals: Aging and Mechanisms of Disease. Publication here. ClinicalTrials.gov Identifier: NCT02678611

  • Menopausal Syndromes

    Working in partnership with the University of South Alabama, this pilot study evaluated the effects of Basis supplementation on menopausal syndromes. The study is complete and expected to publish in 2025. ClinicalTrials.gov Identifier: NCT04841499

  • EH301 for ALS

    Working in collaboration with the Spanish Foundation for ALS Research (FUNDELA), the results of this pilot study showed evidence the experimental therapeutic EH301 can be used in treatment of amyotrophic lateral sclerosis (ALS). Publication here. ClinicalTrials.gov Identifier: NCT03489200

  • NO-ALS (EH301)

    Initiated with partners at Haukeland University Hospital and funded by a grant from the Norwegian government, this human clinical trial is evaluating the efficacy of the experimental therapeutic EH301 for the potential treatment of ALS. We expect the study to be completed by the end of 2025. ClinicalTrials.gov Identifier: NCT04562831

  • COPD (NR-E)

    Initiated at the University of Copenhagen and funded by a grant from the Danish government, this clinical trial evaluated the effect of Elysium’s proprietary nicotinamide riboside (NR-E) on clinical outcomes in elderly patients with COPD. The study results, which are in pre-print, showed that NR-E supplementation supported a healthy inflammation response in the lungs. ClinicalTrials.gov Identifier: NCT04990869

    • Academic Partnerships

    We’ve established multi-year research partnerships with leading institutions to break new ground in aging research.

    • Partnership with the University of Oxford

      Matter, our breakthrough product clinically proven to slow age-related brain atrophy, was developed in partnership with the University of Oxford and world-renowned scientist A. David Smith, Ph.D., Professor Emeritus of Pharmacology at the University of Oxford, Founding Director of OPTIMA, and Elysium Scientific Advisory Board member.

    • Partnership With Yale University

      Elysium partnered with Morgan Levine, Ph.D., of Yale University and a leading researcher in the field of epigenetic predictors of age to develop Index, our revolutionary at-home epigenetic test.

    • The Oxford-Elysium Fellowship Program

      Elysium has established the Oxford-Elysium Fellowship program at the University of Oxford, which recruits the best researchers to work in cutting-edge laboratories. 

      The first fellow, Hanlin Zhang, discovered a new pathway for autophagy induction. Zhang works in the lab of Katja Simon, Professor of Immunology in the Kennedy Institute of Rheumatology in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences. Elysium owns first rights to all intellectual property developed by the fellow.

      The second fellow, Adam Rolt, works in the lab of Lynne Cox at the University of Oxford’s Cox Lab of Ageing and Cell Senescence. Cox’s lab focuses on the genes and biochemical pathways that influence health outcomes in aging and promote healthy aging by treating age-related diseases at the cause.

      Lewis Taylor is the third fellow in the Oxford-Elysium program, and works in Aarti Jagannath’s lab at the Nuffield Department of Clinical Neuroscience. Taylor’s focus is on researching the relationship between circadian rhythms, chronic disease, and biological age.

      For further details on the Oxford-Elysium program and how to apply for fellowship, read more.

    • Elysium Scholars: Helping Students Study Science

      Elysium’s scholarship program is designed to encourage and assist students pursuing an education in science-related fields. There are currently six students enrolled in an undergraduate degree in a scientific field benefiting from the scholarship.

      “Through Elysium Health's products and research focus on human health, the Elysium Scholars program takes an expansive approach to science. We believe that encouraging young people to pursue a career in any scientific field is a critical step toward future breakthroughs and innovations that may have a meaningful impact on the overall health of our society." - Elysium co-founder and chief scientist Leonard Guarente, Ph.D.

      Elysium Scholars is not currently accepting new applicants.